Atrophic Acne Scars
Conditions
Brief summary
Investigators will collect blood specimens from the participating patients and then blood samples will be centrifuged in order to collect platelet-rich plasma which is going to be injected in the atrophic acne scars. A split-face design is going to used in this randomized controlled trial. In the control side of the face, micro-needling to the skin will occur using a specific tool (Dermapen).
Detailed description
Atrophic acne scar is a common problem with a challenging treatment. Platelet-rich plasma (PRP) is an autologous preparation of platelets in concentrated plasma that may be beneficial in the treatment of atrophic acne scars by promoting collagen deposition. Skin needling is a technique that uses a sterile micro needles to puncture the skin and release growth factors. The combination of skin needling and PRP could enhance the efficacy of both modalities.
Interventions
PROCEDUREPlatelet-Rich Plasma
This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
PROCEDUREMicro-needling
Micro-needling will be applied on the acne scars in one side of the face.
Sponsors
Damascus University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Atrophic acne scars on both sides of the face
Exclusion criteria
* patients with active acne, herpes labialis, or bacterial infection; warts on the face, actinic keratosis, or skin cancer * systemic retinoids intake in the previous 6 months, * diabetes, pregnancy, history of keloidal scarring; or patients with severe systemic illness or malignancy * patients on anticoagulant therapy or aspirin or have a coagulation issue, * patients with hemoglobin less than 10g\\dl or platelet less than 105 micron\\l * any previous procedures for acne scar within the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Scar Appearance | Scar Appearance will be assessed at: T1; one day (wihtin 24 hours) before the application of the intervention(s); and T2: after three months of applying the intervention(s). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patients' Satisfaction | This is going to be assessed six months following the application of the intervention and the active comparator | The assessment will be based on a questionnaire |
Countries
Syria
Outcome results
None listed